We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Drug Cos. Want Blue Cross Unit Sanctioned In Aggrenox MDL

Law360 (February 28, 2018, 6:04 PM EST) -- Boehringer Ingelheim and Teva have asked a Connecticut federal court to sanction Blue Cross and Blue Shield of Louisiana for allegedly dodging discovery in multidistrict litigation in which it’s accusing the drugmakers of entering into a $120 million pay-for-delay deal aimed at blocking generic versions of the stroke-prevention medication Aggrenox.

BCBSLA has repeatedly missed discovery deadlines and didn’t communicate about any issues during that time, and then dumped a still-incomplete but large trove of documents on the drug companies last-minute attached to a deficient privilege log,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.